673 related articles for article (PubMed ID: 28667906)
1. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
[TBL] [Abstract][Full Text] [Related]
2. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
[TBL] [Abstract][Full Text] [Related]
3. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
[TBL] [Abstract][Full Text] [Related]
6. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
7. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.
Michel MC; Mayoux E; Vallon V
Naunyn Schmiedebergs Arch Pharmacol; 2015 Aug; 388(8):801-16. PubMed ID: 26108304
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin improves left ventricular diastolic function of db/db mice.
Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
Lamos EM; Younk LM; Davis SN
Expert Opin Investig Drugs; 2014 Jun; 23(6):875-82. PubMed ID: 24746173
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
16. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
Thomas L; Grempler R; Eckhardt M; Himmelsbach F; Sauer A; Klein T; Eickelmann P; Mark M
Diabetes Obes Metab; 2012 Jan; 14(1):94-6. PubMed ID: 21985693
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
